Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder

Behavioural Brain Research

Volumn 270, Issue , 2014, Pages 349-356

  Kawaura, Kazuaki ^a   Karasawa, Jun ichi ^a   Chaki, Shigeyuki ^a   Hikichi, Hirohiko ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 Trial inhibitory avoidance test; Attention deficit hyperactivity disorder; Clonidine; Guanfacine; Juvenile spontaneously hypertensive rat

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; CLONIDINE; GUANFACINE; METHYLPHENIDATE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;

ALPHA ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; IMPULSIVENESS; LATENT PERIOD; MALE; MENTAL PERFORMANCE; NONHUMAN; PASSIVE AVOIDANCE TEST; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; RAT; STRAIN DIFFERENCE; ANIMAL; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AVOIDANCE BEHAVIOR; COGNITION; DISEASE MODEL; DRUG EFFECTS; INHIBITION (PSYCHOLOGY); NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT OUTCOME; WISTAR KYOTO RAT;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC ALPHA-AGONISTS; ANIMALS; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AVOIDANCE LEARNING; CLONIDINE; COGNITION; DISEASE MODELS, ANIMAL; GUANFACINE; INHIBITION (PSYCHOLOGY); MALE; NEUROPSYCHOLOGICAL TESTS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TREATMENT OUTCOME;

EID: 84902185627     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.05.044     Document Type: Article

References (31)

1. Biederman J., Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 2005, 366:237-248.
2. Arnsten A.F. The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr 2009, 154. I-S43.
3. Reddy D.S. Current pharmacotherapy of attention deficit hyperactivity disorder. Drugs Today 2013, 49:647-665.
4. Fox G.B., Pan J.B., Esbenshade T.A., Bennani Y.L., Black L.A., Faghih R., et al. Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 2002, 131:151-161.
5. Russell V., Allie S., Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav Brain Res 2000, 117:69-74.
6. Arime Y., Kubo Y., Sora I. Animal models of attention-deficit/hyperactivity disorder. Biol Pharm Bull 2011, 34:1373-1376.
7. Sagvolden T. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct 2006, 2:41.
8. Fox G.B. Model of attention deficit hyperactivity disorder: five-trial, repeated acquisition inhibitory avoidance in spontaneously hypertensive rat pups. Current protocols in pharmacology 2004, 1-11. John Wiley & Sons, Inc., Hoboken, NJ, U.S.A., [Chapter 5: Unit 5.37]. S.J. Enna (Ed.).
9. Biederman J., Melmed R.D., Patel A., McBurnett K., Konow J., Lyne A., et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008, 121:e73-e84.
10. Sikirica V., Findling R.L., Signorovitch J., Erder M.H., Dammerman R., Hodgkins P., et al. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs 2013, 27:943-953.
11. Sallee F.R., Kollins S.H., Wigal T.L. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2012, 22:206-214.
12. 2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. J Child Adolesc Psychopharmacol 2013, 23:308-319.
13. Arnsten A.F., Jin L.E. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med 2012, 85:45-58.
14. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic Press, New York. 3rd ed.
15. Delbarre B., Schmitt H. Effects of clonidine and some alpha-adrenoreceptor blocking agents on avoidance conditioned reflexes in rats: their interactions and antagonism by atropine. Psychopharmacologia 1974, 35:195-202.
16. Beyer C.E., Lin Q., Rosenzweig-Lipson S., Schechter L.E. Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine. Eur J Pharmacol 2006, 539:164-167.
17. Sallinen J., Höglund I., Engström M., Lehtimäki J., Virtanen R., Sirviö J., et al. Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol 2007, 150:391-402.
18. Mantsch J.R., Weyer A., Vranjkovic O., Beyer C.E., Baker D.A., Caretta H. Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for β-2 adrenergic receptors. Neuropsychopharmacology 2010, 35:2165-2178.
19. Berridge C.W., Dunn A.J. DSP-4-induced depletion of brain norepinephrine produces opposite effects on exploratory behavior 3 and 14 days after treatment. Psychopharmacology 1990, 100:504-508.
20. Marrs W., Kuperman J., Avedian T., Roth R.H., Jentsch J.D. Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. Neuropsychopharmacology 2005, 30:1500-1510.
21. 2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 2010, 49:1011-1023.
22. Ji X.H., Ji J.Z., Zhang H., Li B.M. Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat. Neuropsychopharmacology 2008, 33:2263-2271.
23. MacDonald E., Kobilka B.K., Scheinin M. Gene targeting - homing in on alpha2-adrenoceptor-subtype function. Trends Pharmacol Sci 1997, 18:211-219.
24. Aoki C., Venkatesan C., Go C.G., Forman R., Kurose H. Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immunocytochemical localization of noradrenergic receptors and axons. Cereb Cortex 1998, 8:269-277.
25. 2C-adrenoceptors. Eur J Pharmacol 2013, 715:328-336.
26. Arnsten A.F., Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005, 57:1377-1384.
27. Mao Z.M., Arnsten A.F., Li B.M. Local infusion of an alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry 1999, 46:1259-1265.
28. Heal D.J., Butler S.A., Prow M.R., Buckett W.R. Quantification of presynaptic alpha-adrenoceptors in rat brain after short-term DSP-4 lesioning. Eur J Pharmacol 1993, 249:37-41.
29. Prieto M., Giralt M.T. Effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on alpha2-adrenoceptors which regulate the synthesis and release of noradrenaline in the rat brain. Pharmacol Toxicol 2001, 88:152-158.
30. Hughes Z.A., Stanford S.C. A partial noradrenergic lesion induced by DSP-4 increases extracellular noradrenaline concentration in rat frontal cortex: a microdialysis study in vivo. Psychopharmacology 1998, 136:299-303.
31. Wang M., Ramos B.P., Paspalas C.D., Shu Y., Simen A., Duque A., et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007, 129:397-410.